Table 3.
Active principles of biological medications prescribed in the cohort of 5596 Italian patients with rheumatoid arthritis, psoriatic arthritis/severe psoriasis, or ankylosing spondylitis from 2006 to 2017.
| First biological medicine prescribed for each patient | Total number of prescriptions | |
|---|---|---|
| Active principle | N (%) | N (%) |
| Abatacept | 53 (4.1) | 1220 (4.1) |
| Adalimumab | 565 (43.3) | 11,746 (39.3) |
| Anakinra | 17 (1.3) | 255 (0.8) |
| Certolizumab pegol | 66 (5.1) | 1288 (4.3) |
| Etanercept | 460 (35.2) | 11,008 (36.9) |
| Golimumab | 68 (5.2) | 2964 (9.9) |
| Infliximab | 31 (2.4) | 317 (1.1) |
| Rituximab | 7 (0.5) | 24 (0.1) |
| Tocilizumab | 38 (2.9) | 1043 (3.5) |